Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher

Investigation on Serum Levels of Interleukin-18 and Interleukin-6 in Patients With Dermatomyositis and Polymyositis

Samaneh Khazaei Asl 1 , Ali Shahraki 1 , * and Zahra Zakeri 2
Authors Information
1 Department of Biology, Faculty of Science, University Of Sistan and Baluchestan, Zahedan, IR Iran
2 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Shiraz E-Medical Journal: February 01, 2016, 17 (2); e34981
  • Published Online: February 28, 2016
  • Article Type: Research Article
  • Received: November 23, 2015
  • Accepted: February 15, 2016
  • DOI: 10.17795/semj34981

To Cite: Khazaei Asl S, Shahraki A, Zakeri Z. Investigation on Serum Levels of Interleukin-18 and Interleukin-6 in Patients With Dermatomyositis and Polymyositis, Shiraz E-Med J. 2016 ; 17(2):e34981. doi: 10.17795/semj34981.

Copyright © 2016, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011; 13(3): 225-32[DOI][PubMed]
  • 2. Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle. 2013; 3(1): 13[DOI][PubMed]
  • 3. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003; 73(2): 213-24[PubMed]
  • 4. Shahraki A, Zakeri Z, Hosseinian M, Hajnegad S. interleukin-33 and interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporosis [in Persian]. J Birjand Univ Med Sci. 2014; 21(1): 86-95
  • 5. Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Estevez E, et al. Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes. 2013; 62(9): 3064-74[DOI][PubMed]
  • 6. Morel JC, Park CC, Woods JM, Koch AE. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem. 2001; 276(40): 37069-75[DOI][PubMed]
  • 7. Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011; 13(2)[DOI][PubMed]
  • 8. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14(6): 705-14[DOI]
  • 9. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci. 2012; 8(9): 1227-36[DOI][PubMed]
  • 10. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6(5): 583-8[DOI][PubMed]
  • 11. Morales-Montor J. The role of the pleiotropic cytokine interleukin-6 (IL-6) during disease. Mod Asp Immunobiol. 2005; 16: 21-6
  • 12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7): 344-7[DOI][PubMed]
  • 13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8): 403-7[DOI][PubMed]
  • 14. Shimojima Y, Ishii W, Matsuda M, Ikeda SI. Phenotypes of peripheral blood lymphocytes and cytokine expression in polymyositis and dermatomyositis before treatment and after clinical remission. Cli Med Insights: Arthritis and musculoskeletal disorders. 2012; 5: 77-87
  • 15. Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014; 53(3): 397-405[DOI][PubMed]
  • 16. De Paepe B, Zschuntzsch J. Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies. Int J Mol Sci. 2015; 16(8): 18683-713[DOI][PubMed]
  • 17. Gono T, Kawaguchi Y, Sugiura T, Ichida H, Takagi K, Katsumata Y, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010; 49(10): 1878-81[DOI][PubMed]
  • 18. Tucci M, Quatraro C, Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp immunol. 2006; 146(1): 21-31[DOI]
  • 19. Tucci M, Quatraro C, Dammacco F, Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci. 2007; 1107: 184-92[DOI][PubMed]
  • 20. Kaser A, Kaser S, Kaneider NC, Enrich B, Wiedermann CJ, Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood. 2004; 103(2): 648-55[DOI][PubMed]
  • 21. Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol. 2004; 173(8): 5312-8[PubMed]
  • 22. Liew FY, Wei XQ, McInnes IB. Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis. 2003; 62 Suppl 2-50[PubMed]
  • 23. Murakami M, Hirano T. The pathological and physiological roles of IL-6 amplifier activation. Int J Biol Sci. 2012; 8(9): 1267-80[DOI][PubMed]
  • 24. Yang M, Cen X, Xie Q, Zuo C, Shi G, Yin G. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol. 2013; 2013: 717808[DOI][PubMed]
  • 25. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000; 164(12): 6593-600[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments